A citation-based method for searching scientific literature

Renato O Crajoinas, Felipe T Oricchio, Thaissa D Pessoa, Bruna P M Pacheco, Lucília M A Lessa, Gerhard Malnic, Adriana C C Girardi. Am J Physiol Renal Physiol 2011
Times Cited: 146







List of co-cited articles
1229 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.
Jean-Pierre Gutzwiller, Stefan Tschopp, Andreas Bock, Carlos E Zehnder, Andreas R Huber, Monika Kreyenbuehl, Heike Gutmann, Jürgen Drewe, Christoph Henzen, Burkhard Goeke,[...]. J Clin Endocrinol Metab 2004
270
44

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.
Charles Pyke, R Scott Heller, Rikke K Kirk, Cathrine Ørskov, Steffen Reedtz-Runge, Peter Kaastrup, Anders Hvelplund, Linda Bardram, Dan Calatayud, Lotte Bjerre Knudsen. Endocrinology 2014
386
35

Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men.
Jeppe Skov, Anders Dejgaard, Jørgen Frøkiær, Jens Juul Holst, Thomas Jonassen, Søren Rittig, Jens Sandahl Christiansen. J Clin Endocrinol Metab 2013
110
34

Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.
Timo Rieg, Maria Gerasimova, Fiona Murray, Takahiro Masuda, Tong Tang, Michael Rose, Daniel J Drucker, Volker Vallon. Am J Physiol Renal Physiol 2012
103
33

Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells.
P Schlatter, C Beglinger, J Drewe, H Gutmann. Regul Pept 2007
102
33

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
33

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.
Minsuk Kim, Mathew J Platt, Tadao Shibasaki, Susan E Quaggin, Peter H Backx, Susumu Seino, Jeremy A Simpson, Daniel J Drucker. Nat Med 2013
295
30

Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells.
Luciene R Carraro-Lacroix, Gerhard Malnic, Adriana C C Girardi. Am J Physiol Renal Physiol 2009
89
31

The physiological role of glucagon-like peptide-1 in the regulation of renal function.
Lívia X S Farah, Vanessa Valentini, Thaissa D Pessoa, Gerhard Malnic, Alicia A McDonough, Adriana C C Girardi. Am J Physiol Renal Physiol 2016
53
52

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
27

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.
R Kodera, K Shikata, H U Kataoka, T Takatsuka, S Miyamoto, M Sasaki, N Kajitani, S Nishishita, K Sarai, D Hirota,[...]. Diabetologia 2011
226
25

Renal effects of glucagon-like peptide in rats.
Carol Moreno, Mahesh Mistry, Richard J Roman. Eur J Pharmacol 2002
80
30

The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential.
Hiroki Fujita, Tsukasa Morii, Hiromi Fujishima, Takehiro Sato, Tatsunori Shimizu, Mihoko Hosoba, Katsushi Tsukiyama, Takuma Narita, Takamune Takahashi, Daniel J Drucker,[...]. Kidney Int 2014
162
23

Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow.
Elisa P Jensen, Steen S Poulsen, Hannelouise Kissow, Niels-Henrik Holstein-Rathlou, Carolyn F Deacon, Boye L Jensen, Jens J Holst, Charlotte M Sorensen. Am J Physiol Renal Physiol 2015
64
35

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
21

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
20

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
20

Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat.
Scott C Thomson, Ali Kashkouli, Prabhleen Singh. Am J Physiol Renal Physiol 2013
49
38

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
19

Liraglutide and Renal Outcomes in Type 2 Diabetes.
Johannes F E Mann, David D Ørsted, Kirstine Brown-Frandsen, Steven P Marso, Neil R Poulter, Søren Rasmussen, Karen Tornøe, Bernard Zinman, John B Buse. N Engl J Med 2017
448
19

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
Kiwon Ban, M Hossein Noyan-Ashraf, Judith Hoefer, Steffen-Sebastian Bolz, Daniel J Drucker, Mansoor Husain. Circulation 2008
727
18

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
18

Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats.
Ming Yu, Carol Moreno, Kimberly M Hoagland, Annette Dahly, Katie Ditter, Mahesh Mistry, Richard J Roman. J Hypertens 2003
218
17

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
Wei Jing Liu, Shu Hua Xie, Yu Ning Liu, Won Kim, Heung Yong Jin, Sung Kwang Park, Yi Ming Shao, Tae Sun Park. J Pharmacol Exp Ther 2012
162
17

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.
Marcel H A Muskiet, Lennart Tonneijck, Mark M Smits, Michaël J B van Baar, Mark H H Kramer, Ewout J Hoorn, Jaap A Joles, Daniël H van Raalte. Nat Rev Nephrol 2017
128
17

Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes.
Akira Mima, Junko Hiraoka-Yamomoto, Qian Li, Munehiro Kitada, Chenzhong Li, Pedro Geraldes, Motonobu Matsumoto, Koji Mizutani, Kyoungmin Park, Christopher Cahill,[...]. Diabetes 2012
111
16

GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting.
Meike Körner, Martin Stöckli, Beatrice Waser, Jean Claude Reubi. J Nucl Med 2007
301
16

GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases.
Hari Hendarto, Toyoshi Inoguchi, Yasutaka Maeda, Noriko Ikeda, Jing Zheng, Ryoko Takei, Hisashi Yokomizo, Eiichi Hirata, Noriyuki Sonoda, Ryoichi Takayanagi. Metabolism 2012
137
16

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal,[...]. N Engl J Med 2017
785
16

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
14

Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice.
Cheol Whee Park, Hyeong Wook Kim, Seung Hyun Ko, Ji Hee Lim, Gyeong Ryul Ryu, Hyun Wha Chung, Sang Woo Han, Seog Jun Shin, Byung Kee Bang, Matthew D Breyer,[...]. J Am Soc Nephrol 2007
156
14

Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model.
Kunio Hirata, Shinji Kume, Shin-ichi Araki, Masayoshi Sakaguchi, Masami Chin-Kanasaki, Keiji Isshiki, Toshiro Sugimoto, Akira Nishiyama, Daisuke Koya, Masakazu Haneda,[...]. Biochem Biophys Res Commun 2009
119
14

Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.
M H A Muskiet, L Tonneijck, M M Smits, M H H Kramer, M Diamant, J A Joles, D H van Raalte. Diabetes Obes Metab 2016
44
31

Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial.
J Skov, M Pedersen, J J Holst, B Madsen, J P Goetze, S Rittig, T Jonassen, J Frøkiaer, A Dejgaard, J S Christiansen. Diabetes Obes Metab 2016
62
22

Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen.
Keizo Kanasaki, Sen Shi, Megumi Kanasaki, Jianhua He, Takako Nagai, Yuka Nakamura, Yasuhito Ishigaki, Munehiro Kitada, Swayam Prakash Srivastava, Daisuke Koya. Diabetes 2014
216
13

Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule.
Adriana Castello Costa Girardi, Lívia Emy Fukuda, Luciana Venturini Rossoni, Gerhard Malnic, Nancy Amaral Rebouças. Am J Physiol Renal Physiol 2008
75
17

Role of dipeptidyl peptidase IV in regulating activity of Na+/H+ exchanger isoform NHE3 in proximal tubule cells.
Adriana C C Girardi, Felix Knauf, Hans-Ulrich Demuth, Peter S Aronson. Am J Physiol Cell Physiol 2004
82
15

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.
Lazaros A Nikolaidis, Sunil Mankad, George G Sokos, Glen Miske, Ankur Shah, Dariush Elahi, Richard P Shannon. Circulation 2004
643
13

Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans.
Jean-Pierre Gutzwiller, Petr Hruz, Andreas R Huber, Christian Hamel, Carlos Zehnder, Juergen Drewe, Heike Gutmann, Zeno Stanga, Daniel Vogel, Christoph Beglinger. Digestion 2006
75
17

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
13

The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?
Marcel H A Muskiet, Mark M Smits, Linde M Morsink, Michaela Diamant. Nat Rev Nephrol 2014
114
13

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
13

Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes.
Julie A Lovshin, Annette Barnie, Ariana DeAlmeida, Alexander Logan, Bernard Zinman, Daniel J Drucker. Diabetes Care 2015
98
13

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
Lennart Tonneijck, Mark M Smits, Marcel H A Muskiet, Trynke Hoekstra, Mark H H Kramer, A H Jan Danser, Michaela Diamant, Jaap A Joles, Daniël H van Raalte. Diabetologia 2016
57
22

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Katherine R Tuttle, Mark C Lakshmanan, Brian Rayner, Robert S Busch, Alan G Zimmermann, D Bradley Woodward, Fady T Botros. Lancet Diabetes Endocrinol 2018
174
13

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction.
Per-Henrik Groop, Mark E Cooper, Vlado Perkovic, Angela Emser, Hans-Juergen Woerle, Maximilian von Eynatten. Diabetes Care 2013
192
12

Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism.
Thomas Nyström, Adrian T Gonon, Ake Sjöholm, John Pernow. Regul Pept 2005
151
12

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
702
12


Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats.
Bruna Pm Pacheco, Renato O Crajoinas, Gisele K Couto, Ana Paula C Davel, Lucília M Lessa, Luciana V Rossoni, Adriana Cc Girardi. J Hypertens 2011
96
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.